Cytokinetics (CYTK) to Release Earnings on Thursday

Key Points

• Cytokinetics (CYTK) is set to announce its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($1.32) per share and revenue of $1.95 million.
• In its last earnings report for Q1 2025, Cytokinetics beat estimates with a loss of ($1.36) per share, while revenue increased 89.1% year-over-year to $1.60 million.
• The stock has a market capitalization of $4.32 billion and a consensus rating of "Moderate Buy" from analysts, with an average target price of $70.92.

Cytokinetics (NASDAQ:CYTK - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.32) per share and revenue of $1.95 million for the quarter.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.41) by $0.05. The business had revenue of $1.60 million for the quarter, compared to analysts' expectations of $2.77 million. During the same quarter last year, the company earned ($1.33) earnings per share. The firm's revenue for the quarter was up 89.1% on a year-over-year basis. On average, analysts expect Cytokinetics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cytokinetics Price Performance

Shares of CYTK stock traded down $0.95 during trading hours on Friday, reaching $36.69. 1,088,724 shares of the stock were exchanged, compared to its average volume of 1,279,881. The business's fifty day moving average is $34.41 and its two-hundred day moving average is $39.13. The firm has a market capitalization of $4.38 billion, a P/E ratio of -6.94 and a beta of 0.64. Cytokinetics has a 12-month low of $29.31 and a 12-month high of $59.39.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,000 shares of the firm's stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $37.47, for a total value of $74,940.00. Following the sale, the executive vice president directly owned 140,610 shares of the company's stock, valued at approximately $5,268,656.70. This trade represents a 1.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Md Kaye sold 3,636 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $32.10, for a total value of $116,715.60. Following the completion of the sale, the director directly owned 29,658 shares in the company, valued at approximately $952,021.80. The trade was a 10.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,751 shares of company stock valued at $1,424,731. 2.70% of the stock is owned by company insiders.

Institutional Trading of Cytokinetics

An institutional investor recently raised its position in Cytokinetics stock. Millennium Management LLC boosted its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 361.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 287,901 shares of the biopharmaceutical company's stock after buying an additional 225,576 shares during the period. Millennium Management LLC owned 0.24% of Cytokinetics worth $11,571,000 at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CYTK. Needham & Company LLC reaffirmed a "buy" rating and set a $72.00 price target on shares of Cytokinetics in a report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $120.00 price objective on shares of Cytokinetics in a research report on Monday, April 21st. Bank of America dropped their price target on Cytokinetics from $62.00 to $54.00 and set a "neutral" rating for the company in a research report on Tuesday, April 15th. Mizuho dropped their price target on Cytokinetics from $103.00 to $84.00 and set an "outperform" rating for the company in a research report on Thursday, May 29th. Finally, Royal Bank Of Canada dropped their price target on Cytokinetics from $82.00 to $80.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $70.92.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.